Advertisement
U.S. markets closed
  • S&P 500

    5,137.08
    +40.81 (+0.80%)
     
  • Dow 30

    39,087.38
    +90.98 (+0.23%)
     
  • Nasdaq

    16,274.94
    +183.04 (+1.14%)
     
  • Russell 2000

    2,076.39
    +21.55 (+1.05%)
     
  • Crude Oil

    79.81
    -0.16 (-0.20%)
     
  • Gold

    2,091.60
    -4.10 (-0.20%)
     
  • Silver

    23.25
    +0.10 (+0.43%)
     
  • EUR/USD

    1.0846
    +0.0039 (+0.36%)
     
  • 10-Yr Bond

    4.1800
    -0.0720 (-1.69%)
     
  • GBP/USD

    1.2660
    +0.0034 (+0.27%)
     
  • USD/JPY

    149.9770
    -0.0070 (-0.00%)
     
  • Bitcoin USD

    62,818.87
    +893.97 (+1.44%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,682.50
    +52.48 (+0.69%)
     
  • Nikkei 225

    39,910.82
    +744.62 (+1.90%)
     

AEON Biopharma Investors Contribute Additional $20 Million to SPAC Deal

By IPO Edge Editorial Staff

Biopharmaceutical company AEON Biopharma, Inc. has raised an additional $20 million in funding from existing investors to support its going-public transaction with Priveterra Acquisition Corp. (Nasdaq: PMGM).

The additional capital represents nearly half of the minimum cash requirement for the proposed transaction, which was announced in December.

AEON, which was founded in 2019 by Allergan veteran Marc Forth who was formerly head of the BOTOX® Therapeutic franchise in the United States, focuses on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications.

“The additional commitment of at least $20 million by existing AEON investors further solidifies our capital position as we seek to advance the development of ABP-450 for patients with debilitating medical conditions, such as migraines,” said Mr. Forth, who is CEO and President of AEON Biopharma. “We look forward to a successful transaction with Priveterra in the public setting as they have a clear understanding of our business and have an established track record of creating value in the life sciences. We are grateful for the continued support of our investors who to date have invested a total of approximately $132 million to pursue therapeutic indications and who recognize the opportunity provided by our clinical development strategy and the unique value proposition we believe we can offer patients, physicians, payors and investors.”

Contact:

IPO Edge

www.IPO-Edge.com

Editor@ipo-edge.com

 

Advertisement